For purposes of classification, a patient is said to have GCA if at least three of these five criteria are present (sensitivity of 93.5% and a specificity of 91.2%).

Objective Recently the Diagnostic and Classification Criteria in Vasculitis Study group developed and published new American College of Rheumatology/EULAR classification criteria for giant cell ...

Introduction. In 1990, the American College of Rheumatology (ACR) published criteria for the classification of seven types of systemic vasculitis, including giant cell arteritis (GCA).1 These criteria ...

Classification as GCA or non-GCA followed the 1990 American College of Rheumatology criteria for GCA. The sensitivity and specificity of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ...

Background: We have been developing a rheumatologist-led ultrasound driven giant cell arteritis (GCA) fast-track pathway (FTP), which in year 3 had the following structure: 1. 1. Rapid access to ...

Giant Cell Arteritis (GCA) presents significant diagnostic and treatment challenges, given its systemic nature, primarily targeting large, and medium-sized arteries in patients over 50. Without timely ...

Objective To develop and validate updated classification criteria for giant cell arteritis (GCA). Methods Patients with vasculitis or comparator diseases were recruited into an international cohort.

Access free, up-to-date clinical references for comprehensive information on the diagnostic criteria of multiple sclerosis at Healio. Our content provides valuable insights for physicians.

Share on Pinterest Newly revised diagnostic criteria for Alzheimer’s may help improve disease prognosis. Image credit: Bloomberg Creative/Getty Images. About 32 million people around the world ...

“The revised criteria, guided by the biology of Alzheimer’s disease and reflecting recent advances in biomarker detection, promise to significantly enhance diagnostic accuracy and patient care ...

In an 18-month study of people who were in the early stages of Alzheimer’s disease, the antibody lecanemab – which the US Food and Drug Administration approved in 2023 – slowed the rate of ...

Since the draft criteria were released, the Alzheimer’s Association has clarified that these are not meant to serve as detailed diagnostic guidelines for clinicians.